{"category":{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"pr","added_at":"2026-09-03T06:07:27.677Z","updated_at":"2026-09-03T06:07:27.677Z","example":false,"profile_url":"/industries/cell-therapy","is_stub":true,"member_count":8,"member_counts":{"company":8}},"members":[{"listing_type":"company","name":"SpectaCell","slug":"spectacell","tagline":"Label-free single-cell analysis platform for immunotherapy potency testing","description":"SpectaCell is a Ghent-based life sciences company spun out of imec, VIB and Ghent University. Its platform combines chip-based imaging with data analysis to track large numbers of individual cells and their interactions directly, at high resolution and over time, without fluorescent labels, so developers can see how a treatment affects individual cells. It targets immunotherapies such as cell therapies (including CAR-T) and T-cell engagers, and is developing a cartridge-based instrument meant to deliver results in hours rather than days, for use from early R&D through manufacturing quality checks. Founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde and Tony Montoye (CEO), it launched in October 2026 with €6M in seed financing led by imec.xpand, with PMV's Flanders Future Tech Fund, InnovationQuarter Capital, Qbic and VIB participating (per imec).","url":"https://www.spectacell.com/","is_stealth":false,"normalized_domain":"spectacell.com","normalized_url_key":"spectacell.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/spectacell/","platform":"linkedin"},{"label":"imec launch announcement","url":"https://www.imec-int.com/en/press/spectacell-launches-eu6-million-transform-drug-development-and-bring-better-immune-therapies"},{"label":"News","url":"https://www.spectacell.com/news/"}],"entry_points":[{"kind":"homepage","url":"https://www.spectacell.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.spectacell.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://www.spectacell.com/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Tony Montoye","role":"Co-founder & CEO","person_slug":"tony-montoye-1eavhwbeplj8q","bio":null,"location":null,"links":[]},{"name":"Mathieu Rabaey","role":"Co-founder","person_slug":"mathieu-rabaey-01u10b5g28wx4","bio":null,"location":null,"links":[]},{"name":"Veronique De Vroey","role":"Co-founder","person_slug":"veronique-de-vroey-3ndwpqi76f1sv","bio":null,"location":null,"links":[]},{"name":"Jan Van de Velde","role":"Co-founder","person_slug":"jan-van-de-velde-2b5hojj1jj034","bio":null,"location":null,"links":[]}],"media":null,"categories":["Biotech","Life Sciences Tools","Cell Therapy","Drug Development"],"stage":"seed","founded_year":null,"location":"Ghent, Belgium","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/spectacell/","contact_email":null,"added_at":"2026-10-09T13:54:26.869Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-09T13:54:26.869Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"drug-development","name":"Drug Development","note":null,"profile_url":"/industries/drug-development"},{"kind":"industry","slug":"life-sciences-tools","name":"Life Sciences Tools","note":null,"profile_url":"/industries/life-sciences-tools"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-09T13:54:26.869Z","updated_at":"2026-10-09T13:54:26.869Z"}},{"listing_type":"company","name":"Celaid Therapeutics","slug":"celaid-therapeutics","tagline":"Expanded hematopoietic stem-cell therapies for blood diseases and genetic disorders","description":"Celaid Therapeutics is a Tokyo-based biotech developing cell therapies built on hematopoietic stem cells (HSCs), the stem cells that produce blood. Its in-vitro expansion technology grows functional, blood-reconstituting HSCs in large quantities without animal-derived components such as albumin and cytokines, aiming to make high-quality cells available at lower cost. Its lead program, CLD-001, is an ex vivo-expanded HSC therapy from umbilical cord blood for severe pediatric non-malignant diseases; the company has reported positive nonclinical data, transferred manufacturing to a U.S. CDMO and completed a pre-IND meeting with the FDA. Established in October 2020 and led by President and CEO Nobuyuki Arakawa, Celaid announced on October 5, 2026 the second close of its Series B, raising JPY 400 million (about USD 2.6 million) from new investors Shionogi and Teikoku Ventures, bringing cumulative funding including AMED grants to about JPY 3.42 billion.","url":"https://celaidtx.com/en/","is_stealth":false,"normalized_domain":"celaidtx.com","normalized_url_key":"celaidtx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://celaidtx.com/wp/wp-content/themes/celaid/img/ogp_en.jpg","links":[{"label":"Series B second close announcement","url":"https://celaidtx.com/en/news/1204/"},{"label":"Press release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/celaid-therapeutics-completes-second-close-of-series-b-financing-round-302893509.html"},{"label":"Shionogi investment announcement","url":"https://www.shionogi.com/global/en/news/2026/10/20261005.html"}],"entry_points":[{"kind":"homepage","url":"https://celaidtx.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"contact","url":"https://celaidtx.com/en/contact/","audience":"human","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://celaidtx.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true},"agent":{"kind":"homepage","url":"https://celaidtx.com/en/","audience":"any","primary":true,"listed_by":"community","on_listing_domain":true}},"founders":[{"name":"Nobuyuki Arakawa","role":"President and CEO","person_slug":"nobuyuki-arakawa-0qsnwpq1jn9r3","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"a0990521-c2d9-49d3-aae0-aee0845c1455"},"categories":["Biotech","Cell Therapy","Regenerative Medicine"],"stage":"series-b+","founded_year":2020,"location":"Tokyo, Japan","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-06T01:22:59.595Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-06T01:22:59.595Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"regenerative-medicine","name":"Regenerative Medicine","note":null,"profile_url":"/industries/regenerative-medicine"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-06T01:22:59.595Z","updated_at":"2026-10-06T01:22:59.595Z"}},{"listing_type":"company","name":"RegCell","slug":"regcell","tagline":"Regulatory T-cell therapies to restore immune tolerance in autoimmune disease","description":"RegCell is a biotechnology company developing regulatory T-cell (Treg) therapies for autoimmune diseases and transplantation. Its platform epigenetically reprograms T cells based on discoveries by scientific founder Dr. Shimon Sakaguchi. Headquartered in Emeryville, California, with roots and R&D ties in Japan, RegCell is advancing toward clinical development for autoimmune indications. CEO Michael McCullar, PhD.","url":"https://regcellbio.com/","is_stealth":false,"normalized_domain":"regcellbio.com","normalized_url_key":"regcellbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://regcellbio.com/wp-content/uploads/2025/03/regcell-logo-final.png","links":[{"label":"LinkedIn","url":"https://www.linkedin.com/company/regcell","platform":"linkedin"}],"entry_points":[{"kind":"homepage","url":"https://regcellbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://regcellbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"7d00f287-357c-46d6-8700-36fc72d4b384"},"categories":["Biotech","Healthcare","Cell Therapy","B2B"],"stage":"series-a","founded_year":null,"location":"Emeryville, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/regcell","contact_email":null,"added_at":"2026-09-18T05:04:34.717Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T05:04:34.717Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"b2b","name":"B2B","note":null,"profile_url":"/industries/b2b"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T05:04:34.717Z","updated_at":"2026-09-18T05:04:34.717Z"}},{"listing_type":"company","name":"Modulari-T","slug":"modulari-t","tagline":"We teach your immune system to attack and cure cancer","description":"Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.\n\nModulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.\n\nModulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.\n\nModulari-T is a Y Combinator company (Winter 2023). YC-listed status: Active.","url":"https://modularit.bio/","is_stealth":false,"normalized_domain":"modularit.bio","normalized_url_key":"modularit.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/modulari-t","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://modularit.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://modularit.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","Cell Therapy","Synthetic Biology","Biotech","Oncology"],"stage":null,"founded_year":null,"location":"Montreal, QC, Canada; San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:28:22.865Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2023","Gene Therapy","Cell Therapy","Synthetic Biology","Biotech","Oncology"],"one_liner_for_search":"Modulari-T — We teach your immune system to attack and cure cancer (Y Combinator Winter 2023)","canonical_facts":["Y Combinator batch: Winter 2023","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Modulari-T Biosciences","Regions (per YC): Canada, United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:28:22.865Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:28:22.865Z","updated_at":"2026-09-03T07:28:22.865Z"}},{"listing_type":"company","name":"Eugit Therapeutics","slug":"eugit-therapeutics","tagline":"Enabling Tissue Targeting of Therapies","description":"Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\n\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).\n\nEugit Therapeutics is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://www.eugittx.com/","is_stealth":false,"normalized_domain":"eugittx.com","normalized_url_key":"eugittx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/eugit-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.eugittx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.eugittx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Cell Therapy","Synthetic Biology","Oncology","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; South San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:11:22.895Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","Cell Therapy","Synthetic Biology","Therapeutics","Oncology","Biotechnology"],"one_liner_for_search":"Eugit Therapeutics — Enabling Tissue Targeting of Therapies (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: EUGIT Tx, EUGIT Therapeutics, Eugit, Eugit Therapeutics Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:11:22.895Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:11:22.895Z","updated_at":"2026-09-03T07:11:22.895Z"}},{"listing_type":"company","name":"WhiteLab Genomics","slug":"whitelab-genomics","tagline":"Unleashing the potential of DNA and RNA based therapies using AI","description":"We have developed an AI platform enabling to accelerate the discovery and the design of genomic therapies such as Cell Therapies, RNA Therapies and DNA Therapies.\n\nWhiteLab Genomics is a Y Combinator company (Winter 2022). YC-listed status: Active.","url":"https://whitelabgx.com/","is_stealth":false,"normalized_domain":"whitelabgx.com","normalized_url_key":"whitelabgx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ba69864f65b85fda9f05c3280bc3b39f42500013.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/whitelab-genomics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://whitelabgx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://whitelabgx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Artificial Intelligence","Gene Therapy","Cell Therapy","Genomics"],"stage":null,"founded_year":null,"location":"Paris, Île-de-France, France; Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:11:19.037Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2022","Artificial Intelligence","Gene Therapy","Cell Therapy","Genomics"],"one_liner_for_search":"WhiteLab Genomics — Unleashing the potential of DNA and RNA based therapies using AI (Y Combinator Winter 2022)","canonical_facts":["Y Combinator batch: Winter 2022","YC company status: Active","Team size (per YC directory): 40","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): France, United States of America, Europe, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:11:19.037Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:11:19.037Z","updated_at":"2026-09-03T07:11:19.037Z"}},{"listing_type":"company","name":"LEAH Labs","slug":"leah-labs","tagline":"Living therapies for pets first, and their people next","description":"LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective \"full stack\" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.\n\nLEAH Labs is a Y Combinator company (Winter 2019). YC-listed status: Active.","url":"https://leahlabs.com/","is_stealth":false,"normalized_domain":"leahlabs.com","normalized_url_key":"leahlabs.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/6907f0370b96042be3d0036ddc25c34015a02b50.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/leah-labs","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://leahlabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://leahlabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","CRISPR","Cell Therapy","Drug discovery"],"stage":null,"founded_year":null,"location":"Minneapolis, MN, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:19:07.483Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2019","CRISPR","Cell Therapy","Drug discovery"],"one_liner_for_search":"LEAH Labs — Living therapies for pets first, and their people next (Y Combinator Winter 2019)","canonical_facts":["Y Combinator batch: Winter 2019","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Lifengine Animal Health Laboratories, Incorporated","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:19:07.483Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"crispr","name":"CRISPR","note":null,"profile_url":"/industries/crispr"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:19:07.483Z","updated_at":"2026-09-03T06:19:07.483Z"}},{"listing_type":"company","name":"Indee Labs","slug":"indee-labs","tagline":"Enabling T cell immunotherapy discovery, development and manufacturing","description":"Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.\n\nIndee Labs is a Y Combinator company (Winter 2017). YC-listed status: Active.","url":"https://www.indeelabs.com/","is_stealth":false,"normalized_domain":"indeelabs.com","normalized_url_key":"indeelabs.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ac1b20e8e540ce71927b19ed6cbc32f9956f9290.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/indee-labs","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.indeelabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.indeelabs.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Gene Therapy","Microfluidics","Cell Therapy"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Berkeley, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:07:27.677Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2017","Gene Therapy","Microfluidics","Cell Therapy"],"one_liner_for_search":"Indee Labs — Enabling T cell immunotherapy discovery, development and manufacturing (Y Combinator Winter 2017)","canonical_facts":["Y Combinator batch: Winter 2017","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:07:27.677Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"microfluidics","name":"Microfluidics","note":null,"profile_url":"/industries/microfluidics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:07:27.677Z","updated_at":"2026-09-03T06:07:27.677Z"}}],"total":8,"limit":50,"offset":0}